Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Sublingual Immunotherapy for Allergic Rhinitis Due to Artemisia Annua: a Randomized, Double Blind,Placebo Controlled, Phase III Trial

NCT03990272 is registered in ClinicalTrials.gov with Beijing Tongren Hospital as lead sponsor.

NCT NCT03990272
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03990272 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Sublingual Immunotherapy for Allergic Rhinitis Due to Artemisia Annua: a Randomized, Double Blind,Placebo Controlled, Phase III Trial
Lead sponsor
Beijing Tongren Hospital
Phase
Phase 3
Overall status
Completed
Start date
March 20, 2017
Completion date
October 30, 2017
Enrollment
702 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

allergic rhinitis